MD-ZEROFOX
ZeroFOX , the global leader in Digital Risk Protection, is proud to announce the acquisition of the Cyveillance business from LookingGlass Cyber Solutions, Inc™. The Cyveillance team has over 20 years of experience delivering comprehensive threat intelligence services, protecting the corporate brands, executives, and data of the world's largest and most respected financial services, energy, and public sector organizations. The combination of the ZeroFOX Artificial Intelligence-powered Digital Risk Protection Platform with Cyveillance’s comprehensive threat intelligence data lake and expansive human dark web intelligence capabilities positions ZeroFOX as the world leader in Digital Risk Protection, connecting automated protection and intelligence for organizations of all sizes.
“Our merger with the Cyveillance team fulfills our strategic vision of accelerating our position as the definitive worldwide leader in Digital Risk Protection,” said James C. Foster, CEO of ZeroFOX. “The addition of Cyveillance allows us to further scale our Digital Risk Protection services and expand our threat intelligence capabilities, complementing our renowned AI & remediation capabilities, to address the entire digital threat lifecycle. Our combined customer base and over 400 employees makes us the largest, most proven provider in the Digital Risk Protection market, serving the needs of the world’s most recognized brands.”
Organizations today operate in a world that demands a digital-first approach. The dramatic shift creates a global digital footprint and attack surface on social media, mobile applications, websites, and other external digital platforms. This unprotected public attack surface exposes organizations and their communities to targeted cyber-attacks, data loss, phishing scams, compliance violations, and account takeovers.
“ZeroFOX’s cyber platform powered by Artificial intelligence and Machine Learning is truly impressive. It was clear that we needed to bring these two organizations together to achieve scale overnight to benefit our customers,” said Gilman Louie, co-founder of Alsop Louie and Executive Chairman of LookingGlass Cyber Solutions. “Combined with the rich Cyveillance data, human and machine intelligence and expertise, our customers will now be fully equipped to combat growing digital threats and exert security control back into digital experiences. This new powerhouse company will enable customers to achieve a new level of protection that is unique in the industry. Foster has built a world-class team and I am excited to join it and the ZeroFOX Board of Directors.” Louie serves as the commissioner for the United States National Security Commission for Artificial Intelligence and Chairman of the Federation of American Scientists.
While the scale of threats targeting public platforms makes it difficult for security teams to create actionable intelligence and seek timely remediation, the combined power of the ZeroFOX Digital Risk Protection Platform and Cyveillance’s customer-centric Digital Risk Protection services will give customers unparalleled visibility, analysis, and remediation capabilities to prioritize and mitigate threats at internet scale and speed.
“Since 2005, I have been honored to be a member of the Cyveillance team. With decades of threat intelligence tradecraft experience and a state of the art 24x7 Cyber Security Center, Cyveillance brings a best-in-class data collection and vetting advantage over all other TI providers. This enriched Intelligence delivered within the ZeroFOX Platform will enable customers to achieve a new level of protection that is years ahead of the competition,” said James Carnall, Cyveillance General Manager. “I look forward to partnering with ZeroFOX to deliver timely, relevant and actionable threat intelligence. It’s clear that we will have the most robust Digital Risk Protection and Threat Intelligence portfolio available in the market.”
ZeroFOX will expand its service offerings for existing customers by leveraging the Cyveillance team, technology and their extensive collection of intelligence data. Existing Cyveillance customers will continue to receive custom Digital Risk Protection services and have access to the power of the ZeroFOX Digital Risk Protection Platform and its industry-leading remediation services.
Cyveillance capabilities include:
- Cyveillance Digital Risk Protection Services - A customer-centric Digital Risk Protection managed service that augments the force of information security teams looking to identify, analyze, and disrupt threats to critical assets and data.
- Cyveillance Data Lake - Cyveillance has the world's largest repository of cyber threat intelligence and threat actor information with more than 20 years of data assembled from the surface, deep, and dark web—powering enrichment, contextualization, API feeds, and threat hunting.
- Cyveillance Finished Intelligence - A digital library of actionable and relevant finished intelligence based on primary threat research and a proprietary intelligence data lake.
- Cyveillance Investigation, Analysis and Response Services - Custom investigation and analysis for physical and digital threats. Advanced analysts provide deep-dive reports, security forensics, threat assessments, research projects, and ad-hoc analyst projects. Projects are designed to dynamically apply and incorporate industry best practices into security and risk management programs.
As part of the acquisition, ZeroFOX will continue to exhibit leadership in this new cybersecurity era by establishing a world-class Cybersecurity Center of Excellence in the Washington, D.C., Metro Area with major offices in Reston, Virginia, and Baltimore, Maryland. This includes a state-of-the-art Cybersecurity Operations Center and Executive Briefing facility for demonstrating and leading organizations on cybersecurity trends, best practices, and technology innovations for Digital Risk Protection. ZeroFOX will also continue to grow its Centers of Excellence in the United Kingdom, Latin America, Asia and the Middle East with a focus on security operations and R&D.
ZeroFOX is trusted by global enterprises, serving thousands of customers, including more than 350 financial institutions in every major country. Funding by Intel Capital, NEA, Highland Capital Partners, Redline Capital Management, Hercules Capital, Comcast Ventures, and Core Capital, ZeroFOX has raised over $150 million in funding to date.
About ZeroFOX - ZeroFOX, the global category leader in Digital Risk Protection, safeguards modern organizations from dynamic security risks across the public attack surface including social media, mobile application, surface, deep and dark web, email and domains, and digital collaboration platforms. With complete global coverage and an artificial intelligence-based analysis engine, the ZeroFOX Platform identifies and remediates targeted phishing attacks, credential compromise, data exfiltration, brand hijacking, executive and location threats, and more. The patented ZeroFOX Platform technology processes and protects millions of posts, messages, and accounts daily across the social and digital landscape, spanning LinkedIn, Facebook, Slack, Instagram, Pastebin, YouTube, mobile app stores, domains, cloud-based email, and more.
About Cyveillance - Cyveillance, which was acquired by LookingGlass in 2015, has a rich history of providing customer-centric threat intelligence services to protect the most critical assets of enterprises worldwide. Founded in 1997, Cyveillance delivers an open source intelligence-led approach to security through continuous, comprehensive monitoring and analysis of millions of online data sources to protect client information, infrastructure, and employees from physical and online threats.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005690/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom